Comparison of organ residence time estimation methods for radioimmunotherapy dosimetry and treatment planning--patient studies.

The estimation of organ residence time is essential for high-dose myeloablative regimens in radioimmunotherapy (RIT). Frequently, this estimation is based on a series of simple planar scans and planar processing. The authors previously performed a simulation study which demonstrated that the accuracy of this methodology is limited compared to a hybrid planar/SPECT residence time estimation method. In this work the authors applied this hybrid method to data from a clinical trial of high-dose myeloablative yttrium-90 ibritumomab tiuxetan therapy. Image data acquired from 18 patients were comprised of planar scans at five time points ranging from 1 to 144 h postinjection and abdominal and thoracic SPECT/CT scans obtained at 24 h postinjection. The simple planar processing method used in this work was based on the geometric mean method with energy window based scatter compensation. No explicit background subtraction nor object or source thickness corrections were performed. The SPECT projections were reconstructed using iterative reconstruction with compensations for attenuation, scatter, and full collimator-detector response. Large differences were observed when residence times were estimated using the simple planar method compared to the hybrid method. The differences were not constant but varied in magnitude and sign. For the dose-limiting organ (liver), the average difference was -18% and variation in the difference was 19%, similar to the differences observed in a previously reported simulation study. The authors also looked at the relationship between the weight of the patient and the liver residence time and found that there was no meaningful correlation for either method. This indicates that weight would not be an adequate proxy for an experimental estimate of residence time when choosing the activity to administer for therapy. The authors conclude that methods such as the simple planar method used here are inadequate for RIT treatment planning. More sophisticated methods, such as the hybrid SPECT/planar method investigated here, are likely to be better predictors of organ dose and, as a result, organ toxicities.

[1]  J G Kereiakes,et al.  In vivo quantitation of lesion radioactivity using external counting methods. , 1976, Medical physics.

[2]  S. A. Bush,et al.  High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. , 2003, Blood.

[3]  G T Chen,et al.  An overview of imaging techniques and physical aspects of treatment planning in radioimmunotherapy. , 1993, Medical physics.

[4]  M. Juweid Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: from clinical trials to clinical practice. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[5]  P. N. Badenhorst,et al.  Quantification of the distribution of 111In-labelled platelets in organs , 2004, European Journal of Nuclear Medicine.

[6]  Michael G Stabin,et al.  OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[7]  I. Buvat,et al.  Comparison between 2D and 3D dosimetry protocols in 90Y-ibritumomab tiuxetan radioimmunotherapy of patients with non-Hodgkin's lymphoma. , 2008, Cancer biotherapy & radiopharmaceuticals.

[8]  Yong Du,et al.  Comparison of Residence Time Estimation Methods for Radioimmunotherapy Dosimetry and Treatment Planning—Monte Carlo Simulation Studies , 2008, IEEE Transactions on Medical Imaging.

[9]  H. Malcolm Hudson,et al.  Accelerated image reconstruction using ordered subsets of projection data , 1994, IEEE Trans. Medical Imaging.

[10]  Eric C Frey,et al.  Evaluation of quantitative imaging methods for organ activity and residence time estimation using a population of phantoms having realistic variations in anatomy and uptake. , 2009, Medical physics.

[11]  Daniel H. S. Silverman,et al.  Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin’s lymphoma , 2000, European Journal of Nuclear Medicine.

[12]  I. Bernstein,et al.  Importance of pre-treatment radiation absorbed dose estimation for radioimmunotherapy of non-Hodgkin's lymphoma. , 1997, Nuclear medicine and biology.

[13]  R. Levy,et al.  Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  Eric C Frey,et al.  A Monte Carlo and physical phantom evaluation of quantitative In-111 SPECT , 2005, Physics in medicine and biology.

[15]  K. Ogawa,et al.  A practical method for position-dependent Compton-scatter correction in single photon emission CT. , 1991, IEEE transactions on medical imaging.

[16]  P. Conti,et al.  Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[17]  R. K. Wu,et al.  Absolute quantitation of radioactivity using the buildup factor. , 1984, Medical physics.

[18]  C. Mulhern,et al.  External imaging techniques for quantitation of distribution of I-131 F(ab')2 fragments of monoclonal antibody in humans. , 1984, Medical physics.

[19]  A. Sartorelli,et al.  Clonal variability in beta-globin mRNA content in an interleukin-3-dependent bone marrow cell line transfected with the erythropoietin receptor before and after stimulation with erythropoietin. , 1997, Blood.

[20]  M. Kaminski,et al.  Importance of intra-therapy single-photon emission tomographic imaging in calculating tumour dosimetry for a lymphoma patient , 2005, European Journal of Nuclear Medicine.

[21]  G. Denardo,et al.  A revolution in the treatment of non-Hodgkin's lymphoma. , 1998, Cancer biotherapy & radiopharmaceuticals.

[22]  W. Oyen,et al.  Pretargeted radioimmunotherapy of cancer: progress step by step. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  M. Kaminski,et al.  Volume reduction versus radiation dose for tumors in previously untreated lymphoma patients who received iodine‐131 tositumomab therapy , 2002, Cancer.